These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 9393982)

  • 1. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma.
    Clark J; Lu YJ; Sidhar SK; Parker C; Gill S; Smedley D; Hamoudi R; Linehan WM; Shipley J; Cooper CS
    Oncogene; 1997 Oct; 15(18):2233-9. PubMed ID: 9393982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.
    Skalsky YM; Ajuh PM; Parker C; Lamond AI; Goodwin G; Cooper CS
    Oncogene; 2001 Jan; 20(2):178-87. PubMed ID: 11313942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fusion of a novel gene, RCC17, to the TFE3 gene in t(X;17)(p11.2;q25.3)-bearing papillary renal cell carcinomas.
    Heimann P; El Housni H; Ogur G; Weterman MA; Petty EM; Vassart G
    Cancer Res; 2001 May; 61(10):4130-5. PubMed ID: 11358836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.
    Rao Q; Shen Q; Xia QY; Wang ZY; Liu B; Shi SS; Shi QL; Yin HL; Wu B; Ye SB; Li L; Chen JY; Pan MH; Li Q; Li R; Wang X; Zhang RS; Yu B; Ma HH; Lu ZF; Zhou XJ
    Am J Surg Pathol; 2015 Sep; 39(9):1181-96. PubMed ID: 26274027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
    Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
    [No Abstract]   [Full Text] [Related]  

  • 6. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25.
    Ladanyi M; Lui MY; Antonescu CR; Krause-Boehm A; Meindl A; Argani P; Healey JH; Ueda T; Yoshikawa H; Meloni-Ehrig A; Sorensen PH; Mertens F; Mandahl N; van den Berghe H; Sciot R; Dal Cin P; Bridge J
    Oncogene; 2001 Jan; 20(1):48-57. PubMed ID: 11244503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas.
    Mathur M; Samuels HH
    Oncogene; 2007 Jan; 26(2):277-83. PubMed ID: 16832349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.
    Argani P; Antonescu CR; Illei PB; Lui MY; Timmons CF; Newbury R; Reuter VE; Garvin AJ; Perez-Atayde AR; Fletcher JA; Beckwith JB; Bridge JA; Ladanyi M
    Am J Pathol; 2001 Jul; 159(1):179-92. PubMed ID: 11438465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts.
    Chang IW; Huang HY; Sung MT
    Am J Surg Pathol; 2009 Dec; 33(12):1894-901. PubMed ID: 19809274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequestration.
    Mathur M; Das S; Samuels HH
    Oncogene; 2003 Aug; 22(32):5031-44. PubMed ID: 12902986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23).
    Argani P; Lui MY; Couturier J; Bouvier R; Fournet JC; Ladanyi M
    Oncogene; 2003 Aug; 22(34):5374-8. PubMed ID: 12917640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.
    Martignoni G; Pea M; Gobbo S; Brunelli M; Bonetti F; Segala D; Pan CC; Netto G; Doglioni C; Hes O; Argani P; Chilosi M
    Mod Pathol; 2009 Aug; 22(8):1016-22. PubMed ID: 19396149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
    Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
    Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xp11.2 translocation renal cell carcinoma with NONO-TFE3 gene fusion: morphology, prognosis, and potential pitfall in detecting TFE3 gene rearrangement.
    Xia QY; Wang Z; Chen N; Gan HL; Teng XD; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Mod Pathol; 2017 Mar; 30(3):416-426. PubMed ID: 27934879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene.
    Sidhar SK; Clark J; Gill S; Hamoudi R; Crew AJ; Gwilliam R; Ross M; Linehan WM; Birdsall S; Shipley J; Cooper CS
    Hum Mol Genet; 1996 Sep; 5(9):1333-8. PubMed ID: 8872474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions and clinicopathologic associations.
    Altinok G; Kattar MM; Mohamed A; Poulik J; Grignon D; Rabah R
    Pediatr Dev Pathol; 2005; 8(2):168-80. PubMed ID: 15747097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary PSF/TFE3-associated renal cell carcinoma in a child treated for genitourinary rhabdomyosarcoma.
    Brassesco MS; Valera ET; Bonilha TA; Scrideli CA; Carvalho de Oliveira J; Pezuk JA; Barros Silva GE; Costa RS; Tone LG
    Cancer Genet; 2011 Feb; 204(2):108-10. PubMed ID: 21504709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xp11.2 translocation renal neoplasm with features of TFE3 rearrangement associated renal cell carcinoma and Xp11 translocation renal mesenchymal tumor with melanocytic differentiation harboring NONO-TFE3 fusion gene.
    Yu W; Wang Y; Rao Q; Jiang Y; Zhang W; Li Y
    Pathol Res Pract; 2019 Sep; 215(9):152521. PubMed ID: 31277953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3.
    Xia QY; Wang XT; Zhan XM; Tan X; Chen H; Liu Y; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Am J Surg Pathol; 2017 May; 41(5):663-676. PubMed ID: 28288037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay.
    Argani P; Lal P; Hutchinson B; Lui MY; Reuter VE; Ladanyi M
    Am J Surg Pathol; 2003 Jun; 27(6):750-61. PubMed ID: 12766578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.